Barely Significant
← all excerpts

Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1.

Jpn J Clin Oncol · 2011 · PMC3012894 · PMID 20965941

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

highly significantP < 0.001actually significant
In the overall population, median PFS was 4.90 months (95% CI, 3.98–5.52 months) with everolimus and 1.87 months (95% CI, 1.84–1.94 months) with placebo, translating into a highly significant HR of 0.33 (95% CI, 0.25–0.43; P < 0.001; Fig. 1 B).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.